A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the
 virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early
 symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much
 virus is in the body at various times during the study. Participation could last about 12
 weeks and includes one required visit to the study site, with the remainder of assessments
 performed in the home or by phone.
Inclusion Criteria:

 -  Are currently not hospitalized. (Not applicable to participants in treatment arm 22.)

 -  Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat,
 malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with
 exertion. (Not applicable to participants in treatment arm 22.)

 -  Must have sample taken for test confirming viral infection no more than 3 days prior
 to starting the drug infusion

 -  Are males or females, including pregnant females who agree to contraceptive
 requirements

 -  Understand and agree to comply with planned study procedures

 -  Agree to the collection of nasopharyngeal swabs and venous blood. (Not applicable to
 participants in treatment arms 20-21.)

 -  The participant or legally authorized representative give signed informed consent
 and/or assent

 Participants in treatment arms 7-9, 13-14, and 18-21 ONLY

 -  Are greater than or equal to (≥)18 years of age and must satisfy at least one of the
 following at the time of screening

 -  Are pregnant

 -  Are ≥65 years of age

 -  Have a body mass index (BMI) ≥35

 -  Have chronic kidney disease (CKD)

 -  Have type 1 or type 2 diabetes

 -  Have immunosuppressive disease

 -  Are currently receiving immunosuppressive treatment or

 -  Are ≥55 years of age AND have:

 -  cardiovascular disease (CVD), OR

 -  hypertension, OR

 -  chronic obstructive pulmonary disease (COPD) or other chronic respiratory
 disease

 -  Are 12-17 years of age (inclusive) AND satisfy at least one of the following at the
 time of screening

 -  Are pregnant

 -  Have a body mass index (BMI) ≥85th percentile for their age and gender based on
 CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm

 -  Have sickle cell disease

 -  Have congenital or acquired heart disease

 -  Have neurodevelopmental disorders, for example, cerebral palsy

 -  Have a medical-related technological dependence, for example, tracheostomy,
 gastrostomy, or positive pressure ventilation (not related to COVID-19)

 -  Have asthma or reactive airway or other chronic respiratory disease that requires
 daily medication for control

 -  Have type 1 or type 2 diabetes

 -  Have chronic kidney disease

 -  Have immunosuppressive disease, or

 -  Are currently receiving immunosuppressive treatment

 Participants in treatment arm 22 ONLY

 - Are 0 (≥ 32 weeks gestational age AND ≥ 1.5 kilograms [kg]) to 17 years of age
 (inclusive) AND satisfy at least one of the following risk factors at the time of screening

 -  Are pregnant

 -  Have a BMI ≥85th percentile for their age and gender based on CDC growth charts,
 https://www.cdc.gov/growthcharts/clinical_charts.htm

 -  Have sickle cell disease

 -  Have congenital or acquired heart disease

 -  Have neurodevelopmental disorders, for example, cerebral palsy, autism, or Down
 syndrome (FAIR Health 2020; Spreat et al. 2020)

 -  Have a medical-related technological dependence, for example, tracheostomy,
 gastrostomy, or positive pressure ventilation (not related to COVID-19)

 -  Have asthma, cystic fibrosis, reactive airways disease or other chronic respiratory
 disease that requires daily medication for control

 -  Have type 1 or type 2 diabetes

 -  Have chronic kidney disease

 -  Have immunosuppressive disease, or

 -  Are currently receiving immunosuppressive treatment, or

 -  Are less than (<) one year of age.

 -  Have one or more COVID-19 symptoms

 -  Shortness of breath/difficulty breathing

 -  Fever

 -  Sore throat

 -  Nausea

 -  Diarrhea

 -  Tiredness

 -  Headache

 -  New loss of taste

 -  Nasal congestion/runny nose

 -  Chills

 -  Stomachache

 -  Vomiting

 -  Cough

 -  Muscle/body aches and pain

 -  New loss of smell

 -  Poor appetite or poor feeding (in babies)

 Exclusion Criteria:

 -  Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at
 sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of
 mercury) to fractional inspired oxygen (FiO2) less than (<)300, respiratory rate
 greater than or equal to (≥)30 per minute, heart rate ≥125 per minute due to COVID-19

 -  Require mechanical ventilation or anticipated impending need for mechanical
 ventilation due to COVID-19

 -  Have known allergies to any of the components used in the formulation of the
 interventions

 -  Have hemodynamic instability requiring use of pressors within 24 hours of
 randomization

 -  Suspected or proven serious, active bacterial, fungal, viral, or other infection
 (besides COVID-19) that in the opinion of the investigator could constitute a risk
 when taking intervention

 -  Have any co-morbidity requiring surgery within <7 days, or that is considered
 life-threatening within 29 days

 -  Have any serious concomitant systemic disease, condition or disorder that, in the
 opinion of the investigator, should preclude participation in this study

 -  Have a history of a positive SARS-CoV-2 test prior to the one serving as eligibility
 for this study

 -  Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30
 days before dosing

 -  Have received treatment with a SARS-CoV-2 specific monoclonal antibody

 -  Have received convalescent COVID-19 plasma treatment

 -  Have participated, within the last 30 days, in a clinical study involving an
 investigational intervention. If the previous investigational intervention has a long
 half-life, 5 half-lives or 30 days, whichever is longer, should have passed

 -  Are concurrently enrolled in any other type of medical research judged not to be
 scientifically or medically compatible with this study

 -  Mothers who are breast feeding

 Participants in Treatment Arm 22 ONLY

 -  Have a diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C) in the
 opinion of the investigator

 -  Are currently hospitalized for treatment of COVID-19. Other reasons for
 hospitalization are acceptable.